BCD-267 is an antibody-drug conjugate comprising a monoclonal antibody (United States Adopted Names trastuzumab) targeting human epidermal growth factor receptor 2 (HER2) (footnote 1) and a topoisomerase I inhibitor (footnote 2) (deruxtecan). BCD-267 is being developed as a biosimilar of Enhertu® (United States Adopted Names trastuzumab deruxtecan).
A monoclonal antibody is a protein engineered by scientists in the laboratory, equivalent to the natural antibodies of the immune system, aimed at binding to a specific target site in the human body (footnote 3).
BCD-267 is one of BIOCAD’s drug products under clinical development.
- HER2 is human epidermal growth factor receptors.
- Topoisomerases are a class of isomerase enzymes that affect the DNA topology.
- Weiner LM, Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology. 2010;10(5):317–27.
This website section includes information about an investigational medicinal product for human use.